Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20640886 | 0.84 | KMT2A (0.45) | ALOX15EPHX2KMT2AGLAHPGD | |
| SCHEMBL21124124 | 0.80 | KMT2A (0.48) | EPHX2KMT2AGLAHPGDMEN1 | |
| SCHEMBL25609127 | 0.78 | ALDH1A1 (0.47) | EPHX2KMT2AHPGDMEN1L3MBTL1 | |
| SCHEMBL537492 | 0.77 | KDM4E (0.62) | KMT2AGLAMEN1L3MBTL1KDM4E | |
| SCHEMBL4856268 | 0.77 | PKM (0.48) | EPHX2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL335080 | 0.75 | EPHX2 (0.44) | ALOX15EPHX2KMT2AHPGDMEN1 | |
| SCHEMBL1239542 | 0.75 | ALOX5 (0.65) | KMT2AGLAL3MBTL1ALDH1A1LMNA | |
| SCHEMBL4849226 | 0.75 | PPID (0.51) | EPHX2KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9832496 | 0.74 | KDM4E (0.58) | ALOX15KMT2AGLAMEN1L3MBTL1 | |
| SCHEMBL13148455 | 0.74 | ALOX15 (0.46) | ALOX15EPHX2KMT2AGLATBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719602-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024249517-A1 | ANTI-HIV COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051375-A1 | ANTI-HIV COMPOUNDS | CCR5, CD4, NFATC1 | ALOX15 2174/4885EPHX2 4452/4885KMT2A 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.